Advertisement

Supply Chain



The Food and Drug Administration approved Adamas Pharmaceuticals' drug Gocovri to treat dyskinesia, a side effect of a medication prescribed to most Parkinson's disease patients, reports Reuters.

The Food and Drug Administration will implement a plan to streamline facility inspection and evaluation processes, which are conducted through the agency's Center for Drug Evaluation and Research and Office of Regulatory Affairs, according to Regulatory Focus.

Advertisement

Most Read

Advertisement
Advertisement